HLA and cross-reactive antigen group matching for cadaver kidney allocation

Transplantation

Volumn 64, Issue 7, 1997, Pages 983-991

  Starzl, Thomas E ^a,d   Eliasziw, Michael ^e   Gjertson, David ^b   Terasaki, Paul I ^b   Fung, John J ^a   Trucco, Massimo ^c   Martell, Joan ^c   Mcmichael, John ^a   Scantlebury, Velma ^a   Shapiro, Ron ^a   Donner, Allan ^e  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; CADAVER DONOR; CHILD; CROSS REACTION; FEMALE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; CADAVER; CHILD; CHILD, PRESCHOOL; CROSS REACTIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-DR ANTIGENS; HUMANS; INFANT; MALE; MIDDLE AGED; PENNSYLVANIA; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS;

EID: 0030754437     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199710150-00009     Document Type: Article

References (58)

1. Starzl TE, Shapiro R, Teperman L. The point system for organ distribution. Transplant Proc 1989; 21: 3432.
2. Van Buren CT, Kerman RH, Lewis RM, Kahan BD. Exchanging donor kidneys. N Engl J Med 1988; 319: 1092.
3. Guttman RD. The graft survival curve: ideology and rhetoric. Transplant Proc 1992; 24: 2407.
4. Gaston RS, Ayres I, Dooley LG, Diethelm AG. Racial equity in renal transplantation: the disparate impact of HLA-based allocation. JAMA 1983; 270: 1352.
5. Starzl TE, Fung JJ. The politics of grafting cadaver kidneys. Lancet 1996; 348: 454.
6. Sanfilippo F, Vaughn WK, Spees EK, Heise ER, LeFor WM. The effect of HLA-A, -B matching on cadaver renal allograft rejection comparing public and private specificities. Transplantation 1984; 38: 483.
7. Duquesnoy RJ, White LT, Fierst JW, et al. Multiscreen serum analysis of highly sensitized renal dialysis patients for antibodies toward public and private class I HLA determinants: implications for computer-predicted acceptable and unacceptable donor mismatches in kidney transplantation. Transplantation 1990; 50: 427.
8. Rodey GE, Fuller TC. Public epitopes and the antigenic structure of the HLA molecules. Crit Rev Immunol 1987; 7(3): 229.
9. Takemoto S, Terasaki PI, Gjertson DW, Cecka JM. Equitable allocation of HLA-compatible kidneys for local pools and for minorities. N Engl J Med 1994; 331: 760.
10. Thompson JS, Thacker LR. CREG matching for first cadaveric kidney transplants (TNX) performed by SEOPF centers between October 1987 and September 1995. Clin Transplant 1996; 10: 586.
11. Bodmer JG, Marsh SGE, Albert ED, et al. Nomenclature for factors of the HLA system. Hum Immunol 1997; 53: 98.
12. Zhou YC, Cecka JM. Effect of HLA matching on renal transplant survival. In: Cecka JM, Terasaki PI, eds. Clinical transplants 1993. Los Angeles: UCLA Tissue Typing Laboratory, 1994 499.
13. Starzl TE, Hakala T, Tzakis A, et al. A multifactorial system for equitable selection of cadaveric kidney recipients. JAMA 1987; 257: 3073.
14. Norman DJ, Ellison MD, Breen TJ, Davies DB, Daily OP. Cadaveric kidney allocation in the US: a critical analysis of the point system. Transplant Proc 1995; 27: 800.
15. Takemoto S, Gjertson DW, Terasaki PI. HLA matching: a comparison of conventional and molecular approaches. In: Terasaki PI, Cecka JM, eds. Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1992: 413.
16. Rodey GE, Nalan JF, Whelchel JD, Revels KW, Bray RA. Epitope specificity of HLA class I alloantibodies. I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol. 1994; 39: 272.
17. Dixon WJ, Brown MB, Engelman L, Jennrich RI. BMDP statistical software. Berkeley, CA: University of California Press, 1990: 769.
18. Maldonado G, Greenland S. Simulation study of confounder- selection strategies. Am J Epidemiol 1993; 138: 923.
19. Kleinbaum DG. Survival analysis: a self-learning text. New York: Springer-Verlag, 1996: 104.
20. Opelz G, Mickey MR, Terasaki PI. Calculations of long-term graft and patient survival in human kidney transplantation. Transplant Proc 1987; 9: 27.
21. Takemoto BS, Terasaki PI, Cecka JM, Cho YW, Gjertson DW. Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. N Engl J Med 1992; 327: 834.
22. Gjertson DW. Multifactorial analysis of renal transplants reported to the United Network of Organ Sharing registry: a 1994 update. In: Terasaki PI, Cecka JM, eds. Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1994: 519.
23. Starzl TE, Fung J, Jordan M, et al. Kidney transplantation under FK 506. JAMA 1990; 264: 63.
24. Shapiro R, Jordan ML, Scantlebury VP, et al. Randomized trial of FK506/prednisone versus FK506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc 1993; 25: 669.
25. Starzl TE, Donner A, Eliasziw M, et al. Randomized trialomania? The multicenter liver transplant trials. Lancet 1995; 346: 1346.
26. Starzl TE. Patterns of permissible donor-recipient tissue transfer in relation to ABO blood groups. In: Experience in renal transplantation. Philadelphia: WB Saunders, 1964; 37.
27. Terasaki PI, Marchioro TL, Starzl TE. Sero-typing of human lymphocyte antigens: preliminary trials on long-term kidney homograft survivors. In: Histocompatibility testing. Washington, DC: National Academy of Sciences-National Research Council, 1965: 83.
28. Held PJ, Kahan BD, Hunsicker LG, et al. The impact of HLA mismatches on the survival of first cadaveric kidney transplants. N Engl J Med 1994; 331: 765.
29. Brent L. Immunogenetics; histocompatibility antigens: structure and function. In: A history of transplantation immunology. London: Academic Press, 1997: 131.
30. Meuwissen HJ, Gatti RA, Terasaki PI, Hong R, Good RA. Treatment of lymphopenic hypogammaglobulinemia and bone-marrow aplasia by transplantation of allogeneic marrow: crucial role of histocompatibility matching. N Engl J Med 1969; 281: 691.
31. Thomas ED. Allogeneic marrow grafting: a story of man and dog. In: Terasaki PI, ed. History of transplantation: thirty-five recollections. Los Angeles: UCLA Tissue Typing Laboratory, 1991: 379.
32. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765.
33. Opelz G. HLA matching should be utilized for improving kidney transplant success rates. Transplant Proc 1991; 23: 46.
34. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, chimerism, and graft acceptance. Lancet 1992; 339: 1579.
35. Starzl TE, Demetris AJ, Trucco M, et al. Cell migration and chimerism after whole organ transplantation: the basis of graft acceptance. Hepatology 1993; 17: 1127.
36. Starzl TE, Demetris AJ, Murase N, Trucco M, Thomson AW, Rao AS. The lost chord: microchimerism. Immunol Today 1996; 17: 577.
37. Azuma H, Nadeau K, Mackenzie HS, Brenner BM, Tilney NL. Nephron mass modulates the hemodynamic, cellular, and molecular response of the rat renal allograft. Transplantation 1997; 63: 519.
38. Brenner BM, Milford EL. Nephron underdosing: a programmed cause of chronic renal allograft failure. Am J Kidney Dis 1993; 21: 66.
39. Chertow GM, Milford EL, Mackenzie HS, Brenner BM. Antigen- independent determinants of cadaveric kidney transplant failure. JAMA 1996; 276: 1732.
40. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S, Cho YW, Yuge J. Risk rate and long-term kidney transplant survival. In:. Cecka JM, Terasaki, PI, eds. Clinical transplants 1996. Los Angeles: UCLA Tissue Typing Laboratory, 1996: 443.
41. Gjertson DW, Cecka JM, Terasaki PI. The relative effects of FK 506 and cyclosporine on short- and long-term kidney graft survival. Transplantation 1995; 60: 1384.
42. Starzl TE, Marchioro TL, Terasaki PI, et al. Chronic survival after human renal homotransplantations: lymphocyte-antigen matching, pathology and influence of thymectomy. Ann Surg 1965; 162: 749.
43. Terasaki PI, Vredevoe DL, Mickey MR, et al. Serotyping for homotransplantation. VI. Selection of kidney donors for thirty-two recipients. Ann NY Acad Sci 1966; 129: 500.
44. Starzl TE, Porter KA, Andres G, et al. Long-term survival after renal transplantation in humans: with special reference to histocompatibility matching, thymectomy, homograft glomer-ulonephritis, heterologous ALG, and recipient malignancy. Ann Surg 1970; 172: 437.
45. Rapaport FT, Lawrence HS, Thomas L, Converse JM, Tillett WS, Mulholland JH. Cross-reactions to skin homografts in man. J Clin Invest 1962; 41: 2166.
46. Dausset J, Rapaport FT. The Hu-1 system of human histocompatibility. In: Rapaport FT, Dausset J, eds. Human transplantation. New York: Grune & Stratton, 1968: 369.
47. Rapaport FT, Dausset J. Behavior of HLA-compatible and incompatible skin allografts in human recipients preimmunized with pooled leukocyte extracts obtained from randomly selected donors. Transplantation 1983; 36: 592.
48. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995; 333: 333.
49. D'Alessandro AM, Sollinger HW, Knechtle SJ, et al. Living related and unrelated donors for kidney transplantation: a 28-year experience. Ann Surg 1995; 222: 353.
50. Mickey MR, Kreisler M, Albert ED, Tanaka N, Terasaki PI. Analysis of HLA incompatibility in human renal transplants. Tissue Antigens 1971; 1: 57.
51. Callender CO, Hall LE, Yeager CL, Barber JB, Dunston GM, Pinn-Wiggins VW. Organ donation and blacks: a critical frontier. N Engl J Med 1991; 325: 442.
52. Port FK, Held PJ, Wolfe RA, Garcia JR, Rocher LL. The impact of non-identical ABO cadaveric renal transplantation on waiting times and graft survival. Am J Kidney Dis 1991; 17: 519.
53. Mickey MR, Cook DJ, Terasaki PI. Recipient pool sizes for prioritized HLA matching. Transplantation 1989; 47: 401.
54. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925.
55. Petersdorf EW, Longton GM, Anasetti C, et al. Definition of HLA-DQ as a transplantation antigen. Proc Natl Acad Sci USA 1996; 93: 15358.
56. Petersdorf EW, Longton GM, Anasetti C, et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 1997; 89: 1818.
57. Cho YW, Cecka JM, Terasaki PI. HLA matching effect: better survival rates and graft quality. In: Terasaki PI, Cecka JM, eds. Clinical transplants 1994. Los Angeles: UCLA Tissue Typing Laboratory, 1994: 435.
58. Terasaki PI, Cecka JM, Gjertson DW, Cho Y, Takemoto S, Cohn M. A ten-year prediction for kidney transplant survival. In: Terasaki PI, Cecka JM, eds. Clinical transplants 1992. Los Angeles: UCLA Tissue Typing Laboratory, 1992: 501.